Stirling fishes for trout
Tuesday, 15 July, 2008
Stirling Products North America, a subsidiary of Perth's Stirling Products [ASX: STI] has demonstrated the results of its research into treatment of Loma microsporidial gill disease at an American Fisheries Society meeting.
Loma gill disease, caused by Loma salmonae, is an untreatable disease commonly found in farmed fish, particularly in Pacific salmon and trout.
Research conducted by Stirling demonstrates that the company's ProVale product was more effective at inhibiting Loma infection in rainbow trout when compared with unlicensed products.
ProVale is a beta glucan extract designed to stimulate the immune system.
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
2026 Snow Fellowship recipients to receive $24m in biomedical funding
Australian biomedical researchers Dr Deborah Burnett, A/Prof Sudarshini Ramanathan and Dr Ira...
